Egypt Edition 
MENA+ Edition 
UAE Edition 
Saudi Edition 
AI + Innovation (MENA) 
Logistics (MENA) 
Rameda net income up 60% in 2Q2021
EARNINGS WATCH- Tenth of Ramadan for Pharma Industries and Diagnostic Reagents’ (Rameda) net income rose 60% to EGP 31.5 mn…
Compass raises Rameda stake to 15.4%
Compass ups stake in Rameda: Rameda Pharma’s largest shareholder Equinox Pharma has raised its stake in the company by 2.7%…
Rameda acquires new molecule, Dana gas isn’t complaining
EGX-listed Rameda Pharma has acquired an new anticoagulant molecule, the company said in a press release this morning (pdf). The…
Earnings Watch: Rameda, AMOC
EARNINGS WATCH- Tenth of Ramadan for Pharma Industries and Diagnostic Reagents (Rameda) reported a bottom line growth of 26% y-o-y…
GSK is staying put — for now
GSK puts Egypt exit on the backburner: GlaxoSmithKline has shelved plans to sell its units in Egypt and Tunisia following…
Rameda net income dips in 4Q2020
Rameda Pharma’s net income dipped 14% y-o-y in 4Q2020 to EGP 43.5 mn, down from EGP 50.8 mn in the…
Ibnsina to distribute Bayer meds in Egypt, Rameda looks to invest
Ibnsina Pharma has signed an agreement with Germany’s Bayer to import and distribute products from its OTC and Rx-based portfolios,…
GSK only has eyes for Hikma
GlaxoSmithKline (GSK) has rejected separate takeover bids from Rameda and Acdima for its Egypt arm, focusing instead on talks with…
Something went wrong. Please refresh the page and/or try again.